PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
242.97%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.09%. Joel Greenblatt would investigate if growth quality matches quantity.
262.43%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.67%. Jim Chanos would check for structural cost disadvantages.
191.95%
Growth of 191.95% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
-14.88%
Margin decline while Drug Manufacturers - Specialty & Generic median is -0.07%. Seth Klarman would investigate competitive position.
-63.20%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
149.83%
G&A change of 149.83% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
-15.82%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-103.97%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
81.88%
Operating expenses change of 81.88% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
149.15%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.57%. Jim Chanos would check for waste.
15.31%
Interest expense change of 15.31% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
38.60%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.82%. Jim Chanos would check for overinvestment.
-269.53%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 3.69%. Seth Klarman would investigate causes.
-116.66%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-318.21%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.06%. Seth Klarman would investigate causes.
-21.94%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-102.79%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 8.73%. Seth Klarman would investigate advantages.
-292.84%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 4.14%. Seth Klarman would investigate causes.
-156.23%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-246.51%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is -0.55%. Seth Klarman would investigate advantages.
-299.52%
Net income decline while Drug Manufacturers - Specialty & Generic median is 4.50%. Seth Klarman would investigate causes.
-158.17%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-295.00%
EPS decline while Drug Manufacturers - Specialty & Generic median is 8.24%. Seth Klarman would investigate causes.
-295.00%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 8.28%. Seth Klarman would investigate causes.
2.15%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.07%. Jim Chanos would check for issues.
0.34%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.04%. Jim Chanos would check for issues.